In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Terns Pharmaceuticals Inc (NASDAQ: TERN) closed at $8.54 up 0.65% from its previous closing price of $8.48. In other words, the price has increased by $0.65 from its previous closing price. On the day, 1.07 million shares were traded. TERN stock price reached its highest trading level at $8.61 during the session, while it also had its lowest trading level at $8.22.
Ratios:
For a deeper understanding of Terns Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 27.85 and its Current Ratio is at 27.85. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on June 22, 2023, initiated with a Buy rating and assigned the stock a target price of $16.
On June 07, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $18.
On May 31, 2023, ROTH MKM started tracking the stock assigning a Buy rating and target price of $23.ROTH MKM initiated its Buy rating on May 31, 2023, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’24 when ORBIMED ADVISORS LLC sold 5,188 shares for $10.00 per share. The transaction valued at 51,880 led to the insider holds 755,635 shares of the business.
GORDON CARL L sold 5,188 shares of TERN for $51,880 on Jul 16 ’24. The Director now owns 755,635 shares after completing the transaction at $10.00 per share. On Jul 16 ’24, another insider, Quigley Jill M., who serves as the Director of the company, sold 400 shares for $10.00 each. As a result, the insider received 4,000 and left with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 552342400 and an Enterprise Value of 312115808.
Stock Price History:
The Beta on a monthly basis for TERN is -0.39, which has changed by 0.24127913 over the last 52 weeks, in comparison to a change of 0.21827233 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $10.03, while it has fallen to a 52-week low of $3.26. The 50-Day Moving Average of the stock is 20.86%, while the 200-Day Moving Average is calculated to be 39.79%.
Shares Statistics:
For the past three months, TERN has traded an average of 1.16M shares per day and 1557340 over the past ten days. A total of 64.58M shares are outstanding, with a floating share count of 43.10M. Insiders hold about 33.37% of the company’s shares, while institutions hold 76.41% stake in the company. Shares short for TERN as of 1719532800 were 2686113 with a Short Ratio of 2.33, compared to 1717113600 on 2129832. Therefore, it implies a Short% of Shares Outstanding of 2686113 and a Short% of Float of 4.71.
Earnings Estimates
The stock of Terns Pharmaceuticals Inc (TERN) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.32 and a low estimate of -$0.38, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.32 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.16 and -$1.46 for the fiscal current year, implying an average EPS of -$1.32. EPS for the following year is -$1.37, with 7.0 analysts recommending between -$1.02 and -$1.62.
